Brainstorm cell therapeutics to present at the 12th annual california als research summit

New york, jan. 27, 2022 /prnewswire/ -- brainstorm cell therapeutics inc. (nasdaq: bcli), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that ralph kern, m.d., mhsc, president and chief medical officer of brainstorm cell therapeutics, will provide a corporate and clinical overview at the 12th annual california als research summit, which is being held virtually january 27-28, 2022.
BCLI Ratings Summary
BCLI Quant Ranking